These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 14666734

  • 1. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
    Morisaki T, Matsumoto K, Kuroki H, Kubo M, Baba E, Onishi H, Tasaki A, Nakamura M, Inaba S, Katano M.
    Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
    [Abstract] [Full Text] [Related]

  • 2. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP, Baxevanis CN, Papadopoulos NG, Zarkadis IK, Papacostas P, Michailakis E, Tsiatas ML, Papamichail M.
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [Abstract] [Full Text] [Related]

  • 3. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
    Kan N.
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
    [Abstract] [Full Text] [Related]

  • 4. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
    Kan N.
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
    [Abstract] [Full Text] [Related]

  • 5. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.
    Cancer Res; 2004 Aug 01; 64(15):5461-70. PubMed ID: 15289356
    [Abstract] [Full Text] [Related]

  • 6. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K, Toge T.
    Int J Oncol; 2004 Apr 01; 24(4):959-66. PubMed ID: 15010836
    [Abstract] [Full Text] [Related]

  • 7. [T cell receptor V beta repertoire of locoregional lymphocytes in malignant effusions].
    Miyahara E, Yamaguchi Y, Hihara J, Noma K, Funakoshi M, Takashima I, Sawamura A, Toge T.
    Gan To Kagaku Ryoho; 1995 Sep 01; 22(11):1622-5. PubMed ID: 7574776
    [Abstract] [Full Text] [Related]

  • 8. A new approach to the treatment of malignant effusion.
    Li DJ, Wang YR, Tan XY, Wang HZ, Yao XD, Ba DN.
    Chin Med J (Engl); 1990 Dec 01; 103(12):998-1002. PubMed ID: 2127253
    [Abstract] [Full Text] [Related]

  • 9. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.
    Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M, Kawabata K, Hayashi H, Shiraishi T, Imai S, Tsuchitani T, Mizuta J, Nakagawa M, Fukumoto M.
    Br J Cancer; 1999 May 01; 80(5-6):775-85. PubMed ID: 10360655
    [Abstract] [Full Text] [Related]

  • 10. [Clinical evaluation of intrapleural or peritoneal administration of lentinan and OK-432 for malignant effusion].
    Kawaoka T, Yoshino S, Hazama S, Tangoku A, Oka M.
    Gan To Kagaku Ryoho; 2003 Oct 01; 30(11):1562-5. PubMed ID: 14619464
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M, Wada J, Suzuki H, Tanaka M, Katano M, Morisaki T.
    Anticancer Res; 2009 Mar 01; 29(3):831-6. PubMed ID: 19414316
    [Abstract] [Full Text] [Related]

  • 12. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Teramura Y, Yamasaki S, Hori T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1989 Apr 01; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 Apr 01; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

  • 15. Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
    Miyahara E, Yamaguchi Y, Hihara J, Noma K, Toge T.
    J Exp Ther Oncol; 1996 Jul 01; 1(4):242-50. PubMed ID: 9414411
    [Abstract] [Full Text] [Related]

  • 16. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 17. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 15; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
    Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ.
    Anticancer Res; 2005 Mar 15; 25(4):3047-54. PubMed ID: 16080564
    [Abstract] [Full Text] [Related]

  • 19. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
    Hazama S, Oka M, Yoshino S, Iizuka N, Wadamori K, Yamamoto K, Hirazawa K, Wang F, Ogura Y, Masaki Y.
    Gan To Kagaku Ryoho; 1995 Sep 15; 22(11):1595-7. PubMed ID: 7574768
    [Abstract] [Full Text] [Related]

  • 20. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo.
    Kitsuki H, Katano M, Ikubo A, Morisaki T, Anann K, Tanaka M, Torisu M.
    Clin Immunol Immunopathol; 1996 Mar 15; 78(3):283-90. PubMed ID: 8605704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.